Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study Genovese, M. C., Carlier, H., Erickson, J., Braun, D., Banerjee, S. WILEY-BLACKWELL. 2013: S188

View details for Web of Science ID 000325359201433